tbuckley/cabot-search huggingface dataset:
Plantar basal cell carcinoma in a patient with xeroderma pigmentosum: importance of dermoscopy for early diagnosis of nonpigmented skin cancer
Authors: G. Salerni, N. Cecilia, F. Cabrini, I. Kolm, C. Carrera, L. Alós, J. Malvehy, S. Puig
Journal: British Journal of Dermatology (2011)

Journal Article Plantar basal cell carcinoma in a patient with xeroderma pigmentosum: importance of dermoscopy for early diagnosis of nonpigmented skin cancer Get access G. Salerni, G. Salerni Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar N. Cecilia, N. Cecilia Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar F. Cabrini, F. Cabrini Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar I. Kolm, I. Kolm Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Search for other works by this author on: Oxford Academic Google Scholar C. Carrera, C. Carrera Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, SpainCIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar L. Alós, L. Alós Pathology Service, CDB, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain E‐mail: gabrielsalerni@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar J. Malvehy, J. Malvehy Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, SpainCIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar S. Puig S. Puig Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, SpainCIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 5, 1 November 2011, Pages 1143–1145, https://doi.org/10.1111/j.1365-2133.2011.10452.x Published: 01 November 2011
AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
Authors: Katharine Yen, Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung Choe, Marion Dorsch, David P. Schenkein, Samuel Agresta, Scott Biller, Michael Su
Journal: Blood (2013)
Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo- controlled, randomized phase Ib study
Authors: V D'Hondt, Y Humblet, T Guillaume, S Baatout, C Chatelain, M Berliere, J Longueville, AM Feyens, J de Greve, A Van Oosterom
Journal: Blood (1995)
Distinct Morphological Features of Ruptured Culprit Plaque for Acute Coronary Events Compared to Those With Silent Rupture and Thin-Cap Fibroatheroma
Authors: Jinwei Tian, Xuefeng Ren, Rocco Vergallo, Lei Xing, Huai Yu, Haibo Jia, Tsunenari Soeda, Iris McNulty, Sining Hu, Hang Lee, Bo Yu, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2014)
Abstract 823: Gene expression profiling for oncogenic Kras mutation in mice and human colorectal cancer
Authors: Hiroaki Niitsu, Takao Hinoi, Yasuo Kawaguchi, Kazuhiro Sentani, Naohide Oue, Yusuke Sotomaru, Tomohiro Adachi, Yasufumi Saito, Masashi Miguchi, Masatoshi Kochi, Manabu Shimomura, Wataru Yasui, Hideki Ohdan
Journal: Cancer Research (2015)

Abstract Purpose: Oncogenic KRAS mutations are found in 40-50% of human colorectal cancers. However, specific therapeutics has not been yet available. We aimed to search new therapeutic molecular targets or biomarkers in KRAS mutated colorectal cancers. Experimental design: We generated Apcflox/flox; CDX2P9.5-G22Cre and LSL-KrasG12D; Apcflox/flox; CDX2P9.5-G22Cre mice, that had been considered as sporadic colon cancer mouse model with Kras wild and mutant, respectively. We observed the carcinogenesis at the age of 3-4 weeks by necropsy, and harvested the tumors for gene expression profiling. We compared the gene expression by Microarray (GeneChip, Affymetrix) between each 3 tumors from these mice strains. Genes with &amp;gt;5 fold changes between the two groups were selected as candidate genes, and subsequently narrow these down by bibliographic search for further analyses in human colorectal cancers. Result: In macroscopic findings, extensive polyps were generated in cecum and proximal colon, but not in other site of gastrointestinal tract. Tumors occurred in the both strains were considered as well differentiated adenocarcinomas in hematoxylin-eosin staining. It was confirmed that tumors generated in Apcflox/flox; CDX2P9.5-G22Cre mice had Cre-targeted Apc 580D alleles and wild-type Kras, and that tumors generated in LSL-KrasG12D; Apcflox/flox; CDX2P9.5-G22Cre mice had both Cre-targeted Apc 580D alleles and activated oncogenic KrasG12D. In the subsequent gene expression profiling, we identified 31 genes with &amp;gt;5 fold change in Microarray analyses. Of these, we focused on some genes that showed lower expression in Kras mutant tumor than in Kras wild type tumor. We confirmed the lower expressions of these genes in murine tumors by quantitative RT-PCR, and the lower expression in early-staged human colorectal cancers with oncogenic KRAS mutant by immunohistochemistry staining. To analyze the functions, the retroviral vectors that lead overexpression of these genes were constructed and infected to SW480 and RKO CRC cell lines. Proliferation and migration is being analyzed using these cell lines. Conclusion: We identified novel genes associated with oncogenic KRAS mutation, using the analyses of gene expression in colon cancer mouse model. Citation Format: Hiroaki Niitsu, Takao Hinoi, Yasuo Kawaguchi, Kazuhiro Sentani, Naohide Oue, Yusuke Sotomaru, Tomohiro Adachi, Yasufumi Saito, Masashi Miguchi, Masatoshi Kochi, Manabu Shimomura, Wataru Yasui, Hideki Ohdan. Gene expression profiling for oncogenic Kras mutation in mice and human colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 823. doi:10.1158/1538-7445.AM2015-823
Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy.
Authors: E. Ludwig, R. B. Mendelsohn, Y. Taur, M. Kamboj, S. Nagula, K. Sepkowitz, A. D. Zelenetz
Journal: Journal of Clinical Oncology (2010)

9009 Background: Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication after immunosuppressive therapy and can lead to significant morbidity and mortality. We previously identified 22 HBV reactivations in patients of various nationalities without association with a particular malignancy or medication. Our institution subsequently initiated a standard to screen patients initiating immunosuppressive therapy (chemotherapy and/or corticosteroids) for HBV. We report the prevalence of HBV surface antigen (HBsAg) and HBV core antibody (HBcAb) positivity in the first 6 months of this screening program. Methods: We conducted a prospective quality assurance study of all patients at Memorial Sloan-Kettering Cancer Center who were started on immunosuppressive therapy and screened for HBV from June to December 2009. Screening consisted of serologies for HBsAg and HBcAb. If either test was positive, HBV PCR was measured. Results: During the first 6 months of our screening program (June 18- December 18 2009), 3,343 patients (median age 58, 44% male) were screened for HBV prior to initiation of immunosuppression. Conclusions: In the first 6 months of a routine testing program to detect markers of HBV infection, we found a prevalence of 1.3% for HBsAg and 9% for HBcAb. Only half of those with evidence of HBV surface antigen were from regions endemic for HBV. Our findings demonstrate that risk-group-based screening misses many patients who are at risk for reactivation. We therefore recommend other cancer centers implement a similar universal screening program. Total + Median age (years) Male (%) Born in Asia (%) Detectable PCR HBsAg- HBcAb+ 285 (9%) 61 51 20 7 (2.5%) HBsAg+ HBcAb+ 44 (1.3%) 56 70 52 32 (73%) No significant financial relationships to disclose.
Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis
Authors: Byung-Kwan Lim, Seong-Choon Choe, Jae-Ok Shin, Seong-Hyun Ho, Jong-Mook Kim, Seung-Shin Yu, Sunyoung Kim, Eun-Seok Jeon
Journal: Circulation (2002)

The inflammatory cytokines have an important role in the pathogenesis of viral myocarditis. Inerleukin-1 (IL-1) is one of the major cytokines that modulate the outcome of viral infection. Among the methods for in vivo gene transfer, direct injection of plasmid DNA is one that is simple and feasible. In this study, we expressed human IL-1 receptor antagonist (hIL-1Ra) in the mouse heart by direct injection of a novel plasmid vector and evaluated its effects on coxsackieviral (CVB3) myocarditis.A plasmid vector expressing hIL-1Ra (total 40 microg/mouse) was injected into the heart apex of 8-week-old inbred female Balb/C mice (day 3). On day 0, mice (IL-1Ra-CVB3, n=35) were infected intraperitoneally with 10(4) PFU of CVB3; control mice (pCK-CVB3, n=15) were injected with empty vector on day -3 and infected on day 0. hIL-1Ra was expressed in the heart, reached its peak on day 5, and persisted for 2 weeks. The 14-day survival rate of IL-1Ra-CVB3 was higher (77%) than that of controls (30%, P<0.01). Myocardial virus titers on day 3 were lower in IL-1Ra-CVB3 mice. Myocardial inflammation on day 7 and fibrosis on day 14 were markedly decreased in IL-1Ra-CVB3.These results showed that direct injection of the expression plasmid vector into the heart was an effective method to transfer the cytokine gene in vivo, and expressed IL-1Ra in the heart can modulate the deleterious effect of the host immune response in viral myocarditis.
The specificity versus nonspecificity dilemma: toward identifying therapeutic change agents
Authors: Toksoz B. Karasu
Journal: American Journal of Psychiatry (1986)

The author examines the specificity versus nonspecificity dilemma that characterizes the unresolved question of how psychotherapy works. He explores different meanings and arguments on both sides of the controversy and attempts to identify three therapeutic change agents that all schools of therapy share as the basis of their different techniques: affective experiencing, cognitive mastery, and behavioral regulation. The roles and functions of these agents are discussed with regard to their potential complementarity in clinical practice.
Long‐term treatment outcomes in <scp>G</scp>aucher disease
Authors: Joel Charrow, C. Ronald Scott
Journal: American Journal of Hematology (2015)

Following the treatment of the first Gaucher disease patient with enzyme replacement therapy (ERT), it was clear that ERT had the potential to be transformative with dramatic improvements in systemic manifestations of the disease within 2 years. Following over 20 years existence of the International Collaborative Gaucher Group Gaucher Registry and evidence from ∼6000 patients, the long‐term effects of therapy have been documented. It has been shown that ERT can result in improvements in all clinical and laboratory parameters of nonneuronopathic disease. However, different aspects of the disease, such as hematologic parameters, organ volumes and bone disease do not necessarily respond to therapy at the same rate or to the same extent, and this has had major implications for disease monitoring and for the establishment of therapeutic goals for ERT. Response may be affected by factors such as the timing of therapy initiation, the presence of irreversible complications such as osteonecrosis, and by enzyme dose. It is also apparent that ERT has no impact on neurological aspects of disease and highlights the need for additional or alternative treatment strategies able to meet the needs of patients with neuronopathic disease. Am. J. Hematol. 90:S19–S24, 2015. © 2015 Wiley Periodicals, Inc.
CT pulmonary angiograms: Audit of probability of pulmonary embolus based on questionnaire
Authors: James Finnerty, Maria Phitidis, Sajeev Ranmuthu, Stephen Scott
Journal: European Respiratory Journal (2011)

Following British Thoracic Society guidelines on pulmonary emboli (PE) (2003) indicating that clinical probability should be assessed, we altered the request forms for computed tomography pulmonary angiograms (CTPA): nine questions were added, covering immobility, surgery, cancer, lower limb disease, pregnancy, cardiorespiratory disease, thrombophilia, family history of venous thrombosis, and previous history of venous thromboembolic (VTE) disease. We also introduced questions about the reason for suspecting PE: unexplained breathlessness, shock, pleurisy/haemoptysis, disproportionate breathlessness, and other. All CTPA examinations performed at our institution in 2009 (643 records) were analysed, using logistic regression and Chi-squared as appropriate. Of 643 cases, 122 were confirmed by CTPA to have PE. There was no association between the stated mode of presentation and likelihood of PE.  For risk factors, only a history of VTE influenced likelihood of PE (Odds ratio 2.75, CI 1.49-5.08, p
Ethics and Complementary and Alternative Medicine
Authors: Edzard Ernst
Journal: Annals of Internal Medicine (2003)

Letters3 June 2003Ethics and Complementary and Alternative MedicineEdzard Ernst, MD, PhDEdzard Ernst, MD, PhDPeninsula Medical School; Universities of Exeter & Plymouth, Exeter, Devon EX2 4NT, United KingdomAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-11-200306030-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Adams and colleagues (1) show us how to deal with complementary and alternative medicine (CAM) in a legally, ethically, and politically correct fashion. Despite all this, Ms. P., the patient in Case 1, is likely to develop cancer and die. This outcome would result not only from her preference for CAM over conventional therapy but also from the failure of her health care team to convince her otherwise. Significant proportions of CAM providers advise their clients against certain conventional treatments (2). To some degree, this reflects the failure of conventional medicine to get important messages across. If ...References1. Adams KE, Cohen MH, Eisenberg D, Jonsen AR. Ethical considerations of complementary and alternative medical therapies in conventional medical settings. Ann Intern Med. 2002;137:660-4. [PMID: 12379066] LinkGoogle Scholar2. Schmidt K, Ernst E, Andrews . Aspects of MMR. Survey shows that some homeopaths and chiropractors advise against MMR [Letter]. BMJ. 2002;325:597. [PMID: 12228144] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Peninsula Medical School; Universities of Exeter & Plymouth, Exeter, Devon EX2 4NT, United Kingdom PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEthical Considerations of Complementary and Alternative Medical Therapies in Conventional Medical Settings Karen E. Adams , Michael H. Cohen , David Eisenberg , and Albert R. Jonsen Ethics and Complementary and Alternative Medicine Karen E. Adams Metrics Cited byIntegration of traditional and complementary medicine into medical school curricula: a survey among medical students in Makerere University, UgandaTurning a blind eye and a deaf ear to traditional and complementary medicine practice does not make it go away: a qualitative study exploring perceptions and attitudes of stakeholders towards the integration of traditional and complementary medicine into medical school curriculum in UgandaComplementary therapies for cancer, more good than harm? 3 June 2003Volume 138, Issue 11Page: 940KeywordsBehaviorComplementary and alternative medicineCyclic adenosine monophosphateHealth care ePublished: 3 June 2003 Issue Published: 3 June 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
COPD patient and caregiver assessments of care transition quality
Authors: Donna Goodridge, Shelly Hutchinson, Darcy Marciniuk, Donna Rennie
Journal: European Respiratory Journal (2011)

Background:  The high health care utilization of many patients with advanced COPD may reflect sub-optimal preparation of the patient and caregiver to effectively manage COPD upon discharge.   Purpose:  To examine the assessments of COPD patients and their caregivers regarding care transition quality within two weeks of discharge from hospital.   Design:  This cross-sectional study included 22 dyads (N=44) of patients with advanced COPD (MRC 3, 4 or 5) and their caregivers in two Canadian cities. The Care Transitions Measure (CTM-15) was used to obtain scores from both the patients and caregiver on the quality of care transition. CTM-15 scores range from 0-100, with higher scores indicating higher quality of care transition. Correlations between CTM-15 scores, global rating of health and the Clinical COPD Questionnaire (CCQ) were assessed.   Results:  Median CTM-15 score for patients was 58.9 (IQR= 30.5) compared with 46.7 (IQR= 16.5) for caregivers (NS). The majority of patients did not have clear health goals upon discharge (63.6%) a written plan of care (59.1%). Caregivers did not understand warning signs and symptoms to monitor (72.7%), understand how to manage the patient9s health (68.2%) or have all the information needed to be able to take care of the patient upon discharge (54.5%). CTM-15 scores were negatively correlated with CCQ scores (p=0.04) but not with global rating of health.   Interpretation:  COPD patients and their caregivers require additional preparation for discharge and reported important gaps that have important implications for self-care in the community. CTM-15 scores in this study were lower than those previously reported in geriatric literature.
Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature
Authors: Anca Prica, Ariella Pratzer, Matthew C Cheung, Kim Thompson, Eugenia Piliotis, Neil L Berinstein, Kevin R. Imrie, Rahim Pradhan, Anju Vyas, David Good, Liying Zhang, Rena Buckstein
Journal: Blood (2013)
Personality disorders in treatment-seeking combat veterans with posttraumatic stress disorder
Authors: S M Southwick, R Yehuda, E L Giller
Journal: American Journal of Psychiatry (1993)

Many patients with posttraumatic stress disorder (PTSD) appear to have co-occurring symptoms of character pathology; however, to date there have been no empirical studies of comorbid clinician-rated axis II personality disorders in war veterans with chronic PTSD. The authors' objective was to assess DSM-III-R personality disorders in treatment-seeking combat veterans with PTSD.They used the Personality Disorder Examination, a standardized diagnostic interview for DSM-III-R axis II disorders, to assess DSM-III-R personality disorders in 34 patients with PTSD; 18 of the subjects were inpatients and 16 were outpatients.A high rate of character pathology was observed in both inpatient and outpatient groups. The most frequent disorders for which criteria were met were borderline, obsessive-compulsive, avoidant, and paranoid personality disorders. Inpatients had a higher rate of nearly every personality disorder than did outpatients. Inpatients were significantly more likely to meet diagnostic criteria for paranoid, schizotypal, avoidant, and self-defeating personality disorders.War-related PTSD in treatment-seeking Vietnam veterans is often accompanied by diffuse, debilitating, and enduring impairments in character. Subtyping patients with PTSD on the basis of specific axis II profiles may aid in the selection of more specific and effective treatments.
Abstract 275: VF Characteristics and ICD Shock Success: Differences Between Ischemic and Nonischemic Heart Disease
Authors: Judith L Bonnes, Jeroen Jaspers Focks, Sjoerd W Westra, Marc A Brouwer, Joep L Smeets
Journal: Circulation (2011)

Introduction: From animal studies we know that signal characteristics of ventricular fibrillation (VF) are affected by the presence of myocardial scarring. The impact of the underlying etiology of scar formation, ischemic or nonischemic, is unknown. Whether the origin of scar formation is correlated to shock success has not been thoroughly studied either. Therefore, our aim is to compare signal characteristics of VF and shock success in ICD-patients, with either ischemic or nonischemic heart disease. Methods: Consecutive patients undergoing Medtronic ICD implantation between 2005 and 2011 were studied. After ICD implantation VF was induced to test the device. A first ICD shock of 15J was delivered to terminate VF. Signal analysis was performed on the first 4 seconds of the induced VF. The frequency content of the signal was determined using the Fourier Analysis. In addition, the success rate of the first ICD shock was scored. Results: A total of 229 patients were studied of whom 149 (65%) had ischemic heart disease. The dominant, fundamental and median frequency were significantly lower in patients with ischemic heart disease (Table). Also the organization index was lower. In the ischemic heart disease group 83% (124/149) had a successful first ICD shock compared to 89% (71/80) in patients with nonischemic heart disease (p=0.26). Conclusion: Signal characteristics of induced VF are markedly different between patients with ischemic and nonischemic heart disease. VF in ischemic heart disease is slower, less regular and less organized. Shock success was not affected by the underlying etiology, but in 10-20% of cases a first shock was not sufficient. Identification of patients with a lower shock success is subject to further study.